VRAYLAR SIDE EFFECTS

Call Time Wellness Arkansas today at 479-336-6895 to learn how mental health medications can help you.

What is Vraylar?

Vraylar is the brand name for cariprazine, an atypical antipsychotic approved by the FDA. It was developed by AbbVie and has been available in the United States since 2015.

Vraylar belongs to the same general class as medications like aripiprazole (Abilify) and brexpiprazole (Rexulti), but it has a distinct mechanism of action that sets it apart. It comes in capsule form and is taken once daily.

What is Vraylar Used For?

Vraylar is FDA-approved for four specific indications:

• Manic or mixed episodes associated with bipolar I disorder
• Depressive episodes associated with bipolar I disorder
• Schizophrenia in adults
• Adjunctive treatment for major depressive disorder (MDD)

Each of these uses reflects a different aspect of Vraylar’s pharmacological profile, which makes it one of the more versatile options in its class.

What is Vraylar Used to Treat?

Vraylar is FDA-approved for four psychiatric conditions in adults:

• Bipolar I Disorder – Manic or Mixed Episodes: Treats acute mania, improving symptoms like elevated mood, impulsivity, decreased need for sleep, and disorganized thinking.
• Bipolar I Depression: One of few medications approved specifically for the depressive phase of bipolar I, without the mood-switch risk associated with standard antidepressants.
• Schizophrenia: Reduces both positive and negative symptoms (such as emotional flatness and low motivation) — an area where Vraylar has a notable advantage over older antipsychotics.
• Major Depressive Disorder (MDD): Approved as an add-on to antidepressants when they haven’t provided adequate relief, making it an option for treatment-resistant depression.

Vraylar Dosage

Vraylar dosing varies depending on the condition being treated. It is taken orally once per day and does not require food.

Typical dosage ranges:

• Schizophrenia: Starting dose of 1.5 mg/day; may be increased to 3–6 mg/day based on response
• Bipolar I mania/mixed episodes: Starting dose of 1.5 mg/day; may be increased to 3–6 mg/day
• Bipolar I depression: Starting dose of 1.5 mg/day; target dose of 1.5–3 mg/day
• Adjunctive MDD: Starting dose of 1.5 mg/day; may be increased to 3 mg/day

Dose adjustments are made gradually and based on individual response and tolerability. Vraylar has a long half-life, meaning it stays active in the body for an extended period. This affects both how quickly effects are felt and how long side effects may persist after a dose change.

A prescribing clinician will determine the appropriate dose and monitor for response and side effects over time.

Common Side Effects of Vraylar

The most frequently reported side effects of Vraylar include:

• Akathisia (a feeling of inner restlessness or an urge to move; one of the more common complaints, particularly at higher doses)
• Extrapyramidal symptoms (movement-related side effects including tremor, stiffness, or slowness)
• Nausea
• Drowsiness or sedation
• Vomiting
• Indigestion
• Constipation
• Headache
• Insomnia
• Weight gain (less common with Vraylar than with some other atypical antipsychotics, but possible)

Akathisia is worth noting specifically because it can be distressing and is sometimes mistaken for worsening anxiety or agitation. If this occurs, it should be discussed with the prescribing clinician promptly.

Serious Side Effects and Warnings

• FDA Black Box Warning – Elderly Dementia Patients: Vraylar is associated with increased risk of death in elderly patients treated for dementia-related psychosis and is not approved for this use.
• Suicidal Thoughts: As with antidepressants, monitor closely for worsening mood or suicidal thinking, especially in children, adolescents, and young adults.
• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction (high fever, muscle rigidity, altered mental status). Requires immediate medical attention.
• Tardive Dyskinesia: Long-term use can cause involuntary movements, which may be irreversible. Risk increases with dose and duration.
• Metabolic Changes: May affect blood sugar, cholesterol, and triglycerides; regular monitoring is recommended.
• Orthostatic Hypotension: Can cause dizziness or fainting when standing, especially when starting or adjusting the dose.
• Seizures: May lower the seizure threshold; discuss with your prescriber if you have a seizure history.
• Low White Blood Cell Counts: Those with a history of leukopenia or neutropenia require closer monitoring.

Vraylar Drug Interactions

Vraylar is metabolized by the liver enzyme CYP3A4, which means medications that affect this enzyme can significantly alter Vraylar levels in the body.

• Strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, itraconazole) — Increase Vraylar blood levels; dose reduction is typically required
• Strong CYP3A4 inducers (such as rifampin, carbamazepine, St. John’s Wort) — Decrease Vraylar levels and may reduce effectiveness; dose adjustment may be needed
• CNS depressants (including alcohol, benzodiazepines, opioids, and sedating antihistamines) — Combined use increases sedation and cognitive impairment
• Antihypertensive medications — Vraylar’s potential to cause orthostatic hypotension may be amplified when combined with blood pressure medications

A complete and current medication list should be shared with any prescriber before starting Vraylar or making any changes to an existing regimen.

Stopping Vraylar

Vraylar should not be stopped abruptly without medical guidance. Discontinuing any antipsychotic suddenly can lead to a return of symptoms, and in some cases withdrawal-like effects including nausea, insomnia, and irritability.

Because of Vraylar’s long half-life, some effects of discontinuation may be delayed compared to shorter-acting medications. A gradual taper under the supervision of a prescriber is the standard approach when discontinuation is clinically appropriate.

Vraylar in a Broader Mental Health Treatment Plan

Medication is one component of mental health treatment, and Vraylar works best when paired with consistent therapeutic support and psychiatric monitoring.

For people with bipolar disorder or schizophrenia, therapy helps address the behavioral, relational, and cognitive dimensions of these conditions that medication alone does not fully resolve. Regular psychiatric follow-up allows for dose optimization, side effect management, and coordination with other aspects of care.

A comprehensive plan may include:

• Ongoing psychiatric evaluation and medication monitoring
• Individual therapy (CBT, DBT, or trauma-focused approaches)
• Group therapy and peer support
• Life skills development
• Holistic therapies to support overall stability

How Time Wellness Arkansas Supports People Taking Vraylar

Time Wellness Arkansas integrates psychiatric care and medication management into all of its treatment programs. For clients who are prescribed Vraylar, the clinical team monitors response and side effects, manages any necessary dose adjustments, and ensures the medication is working in concert with therapy and other treatment components.

Available levels of care include:

• Partial Hospitalization Program (PHP) 
• Intensive Outpatient Program (IOP)
• Outpatient Program 
• Virtual Treatment 

The team at Time Wellness Arkansas includes psychiatrists, licensed therapists, and clinical support staff who work together throughout the treatment process.